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Abstract
Pathological inclusions containing aggregated, highly phosphorylated (at serine129) α-synuclein (αS pSer129) are
characteristic of a group of neurodegenerative diseases termed synucleinopathies. Antibodies to the pSer129
epitope can be highly sensitive in detecting αS inclusions in human tissue and experimental models of
synucleinopathies. However, the generation of extensively specific pSer129 antibodies has been problematic, in
some cases leading to the misinterpretation of αS inclusion pathology. One common issue is cross-reactivity to the
low molecular mass neurofilament subunit (NFL) phosphorylated at Ser473. Here, we generated a series of
monoclonal antibodies to the pSer129 αS and pSer473 NFL epitopes. We determined the relative abilities of the
known αS kinases, polo-like kinases (PLK) 1, 2 and 3 and casein kinase (CK) II in phosphorylating NFL and αS, while
using this information to characterize the specificity of the new antibodies. NFL can be phosphorylated by PLK1, 2
and 3 at Ser473; however CKII shows the highest phosphorylation efficiency and specificity for this site. Conversely,
PLK3 is the most efficient kinase at phosphorylating αS at Ser129, but there is overlay in the ability of these kinases
to phosphorylate both epitopes. Antibody 4F8, generated to the pSer473 NFL epitope, was relatively specific for
phosphorylated NFL, however it could uniquely cross-react with pSer129 αS when highly phosphorylated, further
showing the structural similarity between these phospho-epitopes. All of the new pSer129 antibodies detected
pathological αS inclusions in human brains and mouse and cultured cell experimental models of induced
synucleinopathies. Several of these pSer129 αS antibodies reacted with the pSer473 NFL epitope, but 2 clones
(LS3-2C2 and LS4-2G12) did not. However, LS3-2C2 demonstrated cross-reactivity with other proteins. Our findings
further demonstrate the difficulties in generating specific pSer129 αS antibodies, but highlights that the use of multiple
antibodies, such as those generated here, can provide a sensitive and accurate assessment of αS pathology.
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Introduction
Synucleinopathies are a group of neurodegenerative dis-
eases that are characterized by the presence of protein-
aceous inclusions containing aggregated α-synuclein (αS)
[1–4]. These inclusions can occur within neurons in the
form of Lewy bodies (LBs), Lewy neurites and neuronal
cytoplasmic inclusions (NCIs) [1–4], and also within oli-
godendrocytes (glial cytoplasmic inclusions; GCIs).
Synucleinopathies include Parkinson’s disease (PD), de-
mentia with Lewy bodies (DLB) and multiple system
atrophy (MSA) [5, 6], and αS positive inclusions also
occur as a secondary proteinopathy in 50–60 % of
Alzheimer’s disease patients and in many other neurode-
generative disorders [7–15]. Within pathological inclusions
αS is aberrantly, highly (~90 %) phosphorylated at serine
129 (pSer129), while in its normal native state it is only
phosphorylated at ~4 %, making this post translational
modification a useful marker of αS inclusions [16, 17].
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Therefore, antibodies recognizing pSer129 αS can be used
as sensitive tools to detect abnormally aggregated αS in hu-
man brain tissue, as well as in experimental animal and cell
culture studies where αS inclusion formation can be in-
duced to assess the pathological outcome of these abnormal
aggregated forms of αS.
Given the extensive use of pSer129 αS antibodies to as-
sess for the presence of pathological αS inclusions, it is im-
portant to generate and validate the specificity of these
reagents. Indeed many pSer129 αS antibodies can cross-
react with additional phosphorylated proteins and it has
been difficult to generate antibodies that are highly specific
[4, 18]. For example, pSer129 αS antibody, 81A [19] that
had been used in many studies to document the formation
of pathological αS inclusions in model systems of induced
inclusion formation [20–23], was later shown to lead to the
over-representation or misinterpretation of the inclusion
formation due to its strong cross-reaction to the low mo-
lecular mass neurofilament subunit (NFL) phosphorylated
at serine 473 [18]. This issue underscores the importance of
using highly specific and well characterized antibodies.
Herein, we have generated a series of novel monoclonal
pSer129 antibodies and characterized the relative prefer-
ential specificity of casein kinase (CK) II and polo-like ki-
nases (PLK) 1, 2 and 3 to phosphorylate Ser129 in αS and
Ser473 in NFL. Most of these new antibodies demon-
strated some variable cross-reactivity with the pSer473
NFL epitope. However, we also determined that the previ-
ously generated antibody EP1536Y and the new antibodies
LS4-2G12 and LC3-2C2 did not react with phosphory-
lated NFL, although EP1536Y and LC3-2C2 had a ten-
dency to non-specifically react with cellular nuclei. We
demonstrated that the new pSer129 αS antibodies could
be used to detect pathological inclusions in patients with
synucleinopathies, as well as in induced mouse and cell
culture models of αS inclusion formation. Collectively,
these resources will be highly valuable tools for the field to
accurately assess and monitor αS inclusion formation.
Materials and methods
Mouse lines
All procedures were performed according to the NIH
Guide for the Care and Use of Experimental Animals and
were approved by the University of Florida Institutional
Animal Care and Use Committee. BALB/c mice and αS
null (αS KO) mice [24] were obtained from Jackson
Laboratory (Bar Habor, ME). M20 and M83 transgenic
mice overexpressing wild-type and A53T human αS
respectively, were previously described [25] and non-
transgenic/wild-type (WT) littermates were also used.
Stereotaxic [18, 26, 27] and muscle injection procedures
[28] were previously described. NFL null (NFL KO) mice
were previously described [29] and kindly provided by Dr.
Janice Robertson.
Antibodies
Mouse anti-NFL antibody NR4 was obtained from
Sigma-Aldrich (St. Louis, MO). Anti-pSer129 αS rabbit
monoclonal antibody EP1536Y was obtained from
Abcam (Cambridge, MA). Anti-human αS mouse mono-
clonal antibody Syn 204 was previously described [30].
pSer129/81A is a mouse monoclonal antibody that only
reacts with αS when phosphorylated at Ser129 [19], but
also cross-reacts with phosphorylated NFL [18]. Neur-
onal specific rabbit anti-βIII tubulin antibody (T2200)
was obtained from Sigma-Aldrich (St. Louis, MO).
Rabbit polyclonal antibody SNL-4 detects αS residues 2–
12 and was previously described [30].
Generation of new mouse monoclonal antibodies
Peptides (Table 1) designed over the region of interest
were synthesized and purified by GenScript USA Inc
(Piscataway, NJ). Lyophilized peptides were reconstituted
in phosphate buffered saline (PBS) and conjugated to
Imject Maleimide-Activated mcKLH (Thermo Scientific,
Waltham, MA). Injection solutions were prepared by
combining 100 μg KLH-conjugated peptide in 200 μl
PBS with 100 μl of either Freunds complete adjuvant (1st
injection; Sigma Aldrich, St. Louis, MO) or Freunds
incomplete adjuvant (subsequent injections; Sigma
Aldrich, St. Louis, MO) and vortexing for 15 mins until
emulsified. Female BALB/c mice (Jackson Laboratory,
Bar Harbor, ME) were injected subcutaneously. A sec-
ond subcutaneous injection was administered 3 weeks
later. Six weeks following the initial injection, mice were
boosted with an intraperitoneal (IP) injection of 100 μg
KLH-conjugated peptide in PBS. Three days later, mice
were euthanized and spleens were harvested using asep-
tic technique.
Mouse myeloma (Sp2/O-Ag14; ATCC, Manassas, VA)
cells were maintained in high glucose (4.5 g/L) Dulbec-
co’s Modified Eagle Medium (DMEM) with 10 % NCTC
135 Media (Sigma Aldrich, St. Louis, MO), 20 % hybrid-
oma grade fetal bovine serum (FBS; Hyclone, Logan,
UT), 100 U/ml penicillin, 100 U/ml streptomycin,
2 mM L-glutamine, 0.45 mM pyruvate, 1 mM oxaloace-
tate, and 0.2 U/ml insulin at 37 °C and 8 % CO2. Spleens
were gently homogenized in 5 % FBS/Hank’s balanced
salt solution (HBSS; Lonza, Walkersville, MD) and cen-
trifuged to pellet cells. The cell pellet was resuspended in
Table 1 Peptides designed to produce antibodies to pSer129
αS and pSer473 NFL
Peptide Sequence Target
pSer129short CAYEMP(pS)EEGYQ pSer129 αS
pSer129long DNEAYEMP(pS)EEGYQDYEC pSer129 αS
pSer473 CEAKDEPP(pS)EGEAEEE pSer473 NFL
C – cysteine residue added for conjugation to KLH, p – phospho-group
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red blood cell lysis buffer (Sigma Aldrich, St. Louis, MO)
and diluted with HBSS after one minute. The cells were
then washed twice by centrifuging at 100 × g for 10 mins
and resuspended in HBSS. Sp2/O-Ag14 cells were also
washed twice with HBSS. Five million Sp2/O-Ag14 cells
were added to 50 million spleen cells and, after centrifu-
ging at 100 × g for 10 mins onto a culture dish, fusion was
induced with 50 % polyethylene glycol 1450 (PEG; Sigma
Aldrich, St. Louis, MO). After washing with HBSS, cells
were incubated in Sp2/O-Ag14 media at 37 °C with 8 %
CO2 overnight. The next day, the cells were gently de-
tached from the plate and distributed into 96 well plates
with Sp2/O-Ag14 media/0.5 % hybridoma enhancing sup-
plement (Sigma Aldrich, St. Louis, MO)/HAT selection
supplement (Sigma Aldrich, St. Louis, MO).
Hybridoma screening
All hybridoma clones were screened for reactivity to the
injected peptide by enzyme-linked immunosorbent assay
(ELISA). MaxiSorp plates (Thermo Scientific, Waltham,
MA) were coated with 1 μg/ml peptide in PBS and
blocked with 5 % FBS/PBS. Media from the hybridomas
were applied to plates, which were then incubated at
room temperature for 3 h. Next, the plates were washed
with PBS, and incubated with goat anti-mouse secondary
antibody conjugated to horse radish peroxidase (HRP;
Jackson Immuno Research Labs, West Grove, PA) for 1 h
at room temperature. Then, plates were washed and TMB
substrates (Pierce, Rockford, IL) were applied until color
changes were observed. Reactions were then quenched
with 1 M HCl and absorbance was measured at 450 nm.
Clones that were positive by ELISA were transferred to
larger culture plates as needed. The positive clones were
next screened by immunohistochemistry (IHC) of a hu-
man autopsy case with abundant αS pathology.
Immunohistochemistry analyses
Paraffin embedded tissue from αS transgenic and WT
mice are described in Table 2. Paraffin embedded, for-
malin fixed human brain tissue was obtained through
the University of Florida Neuromedicine Human Brain
Tissue Bank (summarized in Table 3). Sequential tissue
sections were deparaffinized with xylenes, and sequentially
rehydrated with graded ethanol solutions (100-70 %).
Antigen retrieval was performed by incubating sections in
0.05 % Tween-20 in a steam bath for 30 mins. Endogen-
ous peroxidase activity was quenched with 1.5 % hydrogen
peroxide/0.005 % Triton X-100/PBS for 20 mins. Sections
were blocked with 2 % FBS/0.1 M Tris, pH 7.6 then incu-
bated with primary antibody overnight at 4 °C. Following
washing with 0.1 M Tris, pH 7.6, sections were incubated
with biotinylated horse anti-mouse IgG or biotinylated
horse anti-rabbit IgG secondary antibody (Vector Labora-
tories, Burlingame, CA) diluted in 2 % FBS/0.1 M Tris
pH 7.6 for 1 h. Next, sections were washed with 0.1 M
Tris, pH 7.6, then incubated with streptavidin-conjugated
HRP (VECTASTAIN ABC kit; Vector Laboratories,
Burlingame, CA) diluted in 2 % FBS/0.1 M Tris pH 7.6 for
1 h. Sections were washed with 0.1 M Tris, pH 7.6, and
then developed with 3, 3′diaminobenzidine (DAB kit;
KPL, Gaithersburg, MD). Reactions were stopped by im-
mersing the slides in 0.1 M Tris, pH7.6, and sections were
counterstained with Mayer’s hematoxylin (Sigma Aldrich,
St. Louis, MO). Next, sections were dehydrated with an
ascending series of ethanol solutions (70–100 %) followed
by xylenes, and coverslipped using cytoseal (Thermo
Scientific, Waltham, MA).
Recombinant αS protein production and purification
Recombinant WT human or mouse αS or human αS
with serine 129 mutated to alanine (S129A) were
expressed in Escherichia coli (E. coli) BL21 (DE3)/RIL
(Agilent Technologies, Santa Clara, CA) using the respect-
ive cDNA cloned into the bacterial expression plasmid
pRK172, and purified as previously described [31, 32].
Protein concentrations were determined by bicinchoninic
acid (BCA) assay using bovine serum albumin (BSA;
Pierce, Rockford, IL) as a standard.
Recombinant NFL protein production and purification
Recombinant WT mouse NFL or mouse NFL with
serine 473 mutated to alanine (S473A) were expressed in
Table 2 Summary of mouse tissue used for immunohistochemical analysis of novel antibodies
Mouse line Treatment Fixative References
M83+/− Intramuscular injection of αS fibrils (motor impaired/terminal) 150 mM NaCl/ 70 % ethanol [28]
M83+/− Intramuscular injection of αS fibrils (motor impaired/terminal) Formalin [28]
M83+/− Cerebral injection of αS fibrils (3 months post-injection) 150 mM NaCl/ 70 % ethanol [26]
M83+/+ Naïve (7 month old; no phenotype) 150 mM NaCl/ 70 % ethanol
M83+/+ Naïve (10–12 month old; motor impaired/terminal) 150 mM NaCl/ 70 % ethanol
M20+/− Cerebral injection of αS fibrils (4 months post-injection) 150 mM NaCl/ 70 % ethanol [27]
M20+/− Cerebral injection of αS fibrils (4 months post-injection) Formalin [27]
WT Naïve 150 mM NaCl/ 70 % ethanol
Rutherford et al. Acta Neuropathologica Communications  (2016) 4:80 Page 3 of 20
E. coli BL21 (DE3)/RIL (Agilent Technologies, Santa
Clara, CA), using the respective cDNA cloned in the
bacterial expression plasmid pET-23d and purified as
previously described [18]. Protein concentrations were
determined by Bradford assay using BSA as a standard.
Radioactive and non-radioactive kinase reactions
To determine which kinases could phosphorylate αS and
NFL, and to what extent, we performed radioactive kin-
ase reactions. NFL and S473A NFL were dialyzed in Tris
or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) overnight to remove the urea. Recombinant
proteins (16.3 pmol; αS, S129A αS, NFL or S473A NFL)
were incubated in 25 μl reactions at 30 °C for 8 h with
60 ng PLK2 (Life Technologies, Carlsbad, CA) or 20 ng
CKII (New England Biolabs, Ipswich, MA), PLK1 or
PLK3 (Life Technologies, Carlsbad, CA), 200 μM adeno-
sine triphosphate (ATP) with γ-32P ATP (PerkinElmer,
Waltham, MA) in manufacturer recommended buffers
(CKII buffer: 50 mM Tris-HCl, pH7.5, 10 mM MgCl2,
0.1 mM ethylenediamietetraacetic acid (EDTA), 2 mM di-
thiothreitol (DTT), 0.01 % Brij 35; PLK1 buffer: 50 mM
HEPES, pH7.5, 10 mMMgCl2, 2.5 mM DTT, 0.01 % Triton
X-100; PLK2 buffer: 25 mM HEPES, pH7.5, 10 mM MgCl2,
5 mM MnCl2, 0.5 mM ethylene glycol-bis(β-aminoethyl
ether)-N,N,N’,N’-tetraacetic acid (EGTA), 0.5 mM Na3VO4,
5 mM β-glycerophosphate, 2.5 mM DTT, 0.01 % Triton X-
100; PLK3 buffer: 25 mM Tris, pH7.5, 10 mM MgCl2,
0.5 mM EGTA, 0.5 mM Na3VO4, 5 mM β-
glycerophosphate, 2.5 mM DTT, 0.01 % Triton X-100). Re-
actions without protein for each kinase, and without kinase
for each protein, were included as control reactions. Each
reaction was performed in triplicate. Reactions were then
absorbed onto P-81 phosphocellulose filters (GE Health-
care, Buckinghamshire, UK) and immersed in 85 mM
phosphoric acid. After extensive washing in 85 mM phos-
phoric acid, the filters were rinsed with acetone, air dried
and placed in scintillation vials with Econo-Safe Liquid
Scintillation cocktail (Research Products International,
Mount Prospect, IL). Radioactivity (32P) incorporation was
measured using an LS5000 TD liquid scintillation counter
(Beckman, Brea, CA).
CKII and PLK3 reactions for immunoblot antibody
testing were performed as before, but without γ-32P
ATP. Sodium dodecyl sulfate (SDS) sample buffer was
added to the reactions which were incubated for 10 mins
at room temperature. Equimolar amounts of protein were
resolved by SDS-PAGE and analyzed by immunoblot.
Sequential biochemical fractionation of mouse nervous
tissue
Mouse nervous tissues were fractionated as described by
Emmer et al. 2011 [33]. Briefly, mice were humanely eu-
thanized, and the brain, brainstem and spinal cord were
harvested. The cortex and brainstem/spinal cord were
dissected and placed in separate tubes. Tissues were ho-
mogenized with 3 volumes per gram of tissue with high
salt (HS) buffer (50 mM Tris, pH7.5, 750 mM NaCl,
20 mM NaF, 5 mM EDTA) with a cocktail of protease
inhibitors (1 mM phenylmethylsulfonyl and 1 mg/ml
each of pepstatin, leupeptin, N-tosyl-L-phenylalanyl
chloromethyl ketone, N-tosyl-lysine chloromethyl ketone
and soybean trypsin inhibitor). The tissue homogenates
then underwent sedimentation at 100,000 × g for 20
mins and the supernatants were removed and kept as
the HS fraction. Pellets were resuspended in 3 volumes
per gram of tissue with HS buffer with 1 % Triton X-100
(HS/T buffer) and centrifuged at 100,000 × g for 20
mins. The supernatants were removed and kept as the
HS/T fraction. The pellets were then homogenized in 3
volumes per gram of tissue with HS buffer with 1 M su-
crose and centrifuged at 100,000 × g for 20 mins to float
the myelin, which was discarded. Pellets were homoge-
nized in 2 volumes per gram of tissue with radioimmu-
noprecipitation assay (RIPA) buffer (50 mM Tris,
pH 8.0, 150 mM NaCl, 5 mM EDTA, 1 % NP-40, 0.5 %
sodium deoxycholate, 0.1 % SDS) plus protease inhibi-
tors and centrifuged at 100,000 × g for 20 mins. Super-
natants were removed and kept as the RIPA fraction.
Pellets were then homogenized in 1 volume per gram of
tissue with 2 % SDS/4 M urea by probe sonication and
kept as the SDS/U fractions. Protein concentrations of
all fractions were determined by BCA assay using BSA
(Pierce, Rockford, IL) as a standard. SDS sample buffer
was added to the fractions which were incubated for 10
mins at 100 °C (HS and HS/T fractions) or at room
temperature (SDS/U fraction only). Equal amounts of
protein (10 μg for HS and HS/T, and 5 μg for SDS/U
fractions) were resolved by SDS-PAGE and analyzed by
immunoblot.
Preparation of total protein lysate from mouse nervous
tissue
Mice were humanely euthanized and the brain and
spinal cord were harvested. The cortex and brainstem/
spinal cord were dissected, placed in separate tubes and
lysed with 2 % SDS/50 mM Tris, pH 7.5. Samples were
sonicated using a probe sonicator until homogenous and
incubated for 10 mins at 100 °C. Protein concentrations
Table 3 Summary of human tissue used for
immunohistochemical analysis of novel antibodies
Neuropathological
diagnosis





MSA Pons, Cerebellum Formalin 2
PD Midbrain Formalin 2
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were determined by BCA assay using BSA as a standard.
SDS sample buffer was added and equal amounts of pro-
tein (5 μg) were resolved by SDS-PAGE and analyzed by
immunoblot.
Immunoblotting analyses
Protein samples were resolved by electrophoresis on 8,
10 or 13 % polyacrylamide gels as indicated, then elec-
trophoretically transferred to nitrocellulose membranes.
Membranes were blocked with 5 % milk/Tris-buffered
saline (TBS) then incubated overnight at 4 °C with pri-
mary antibodies diluted in 5 % milk/TBS (non-phospho
antibodies) or 5 % BSA/TBS (phospho antibodies). Fol-
lowing washing, blots were incubated with HRP conju-
gated goat anti-mouse or donkey anti-rabbit secondary
antibodies (Jackson Immuno Research Labs, West
Grove, PA) diluted in 5 % milk/TBS for 1 h. Following
washing, protein bands were visualized using Western
Lightning-Plus ECL reagents (PerkinElmer, Waltham,
MA) and images were captured using the GeneG-
nome XRQ system and GeneTools software (Syngene,
Frederick, MD).
Primary neuronal-glial cultures
Primary cultures (embryonic) were prepared from E16-
E18 C3HBL/6 or αS null mouse brains. Cerebral cortices
were dissected from E16-E18 mouse brains and were
dissociated in 2 mg/ml papain (Worthington, Lakewood,
NJ) and 50 μg/ml DNAase I (Sigma Aldrich, St. Louis,
MO) in sterile HBSS at 37 °C for 20 mins. They were
washed three times in sterile HBSS to inactivate the pa-
pain and switched to 1 % FBS in Neurobasal-A growth
media (Gibco, Waltham, MA), which includes 1 % Glu-
taMax Supplement (Life Technologies, Carlsbad, CA), B-
27 supplement, 100 U/ml penicillin and 100 μg/ml
streptomycin. The tissue mixture was triturated three
times using a 5 ml pipette followed by a Pasteur pipette,
and strained through a 70 μm nylon cell strainer. The
cell mixture was then centrifuged at 1300 × g for 3 mins,
and resuspended in fresh Neurobasal-A media. They
were then plated on Nunc Lab-Tek II CC2 chamber
slides (Life Technologies, Carlsbad, CA) at around
100,000-200,000 cells/cm2. Cells were maintained in the
Neurobasal-A growth media without FBS at 37 °C in a
humidified 5 % CO2 chamber. The cultures were main-
tained for 6 days followed by another 8 days without or
with 20 μg/ml water bath sonicated mouse αS fibrils pre-
pared as previously described [34, 35].
Immunofluorescence microscopy analysis
For double immunofluorescence analysis, cells were
washed with PBS and fixed with 4 % paraformaldehyde/
PBS. Following PBS washes, cells were blocked with 5 %
FBS/PBS/0.1 % Triton X-100 for 30 mins. Cultures were
stained with primary antibodies followed by Alexa-fluor
488 and 594 conjugated secondary antibodies (Invitrogen,
Fig. 1 In vitro phosphorylation of NFL and αS by CKII and PLK1, 2 and 3. a Amino acid sequences surrounding the target phosphorylation sites
(bold) of Ser129 for αS, and Ser473 for NFL. b Quantitative analysis of the stoichiometric phosphorylation of recombinant αS, S129A αS, NFL and
S473A NFL in in vitro kinase reactions as described in “Materials and methods” with CKII, PLK1, PLK2 or PLK3. All reactions were performed in
triplicate. c Immunoblotting analyses of NFL and S473A NFL used in in vitro kinase reactions with CKII, PLK1, PLK2 or PLK3. Proteins were resolved
onto 8 % polyacrylamide gel and probed with 4F8 (pSer473 NFL) and NR4 (anti-NFL) antibodies. d Immunoblotting analyses of αS and S129A αS
used in in vitro kinase reactions with CKII, PLK1, PLK2 or PLK3. Proteins were resolved onto 13 % polyacrylamide gels and probed with 81A
(pSer129 αS) and Syn 204 (anti-αS). The mobility of molecular mass markers are shown on the left
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Fig. 2 Specificity of novel pSer129 αS antibodies as determined by immunoblotting with NFL and αS proteins phosphorylated in vitro with PLK3
or CKII. NFL, S473A NFL, αS and S129A αS were incubated with PLK3 or CKII. The proteins were resolved onto 13 % polyacrylamide gels and
analyzed by immunoblotting with novel αS antibodies (as indicated above each blot) LS7, LS11, LC2-2C2, LS4-1B1, LS4-2C3 and LS4-2G12 and
novel NFL antibody 4F8, to demonstrate their specificity. NR4 (anti-NFL) and Syn 204 (anti-αS) were included to show each protein, respectively.
Previously reported pSer129 αS antibodies 81A and EP1536Y were included for comparison. Reactions were performed in duplicate. Antibody 4F8,
generated against the pSer473 NFL epitope, can cross react with αS phosphorylated at Ser129. Antibodies 81A, LS11, LS4-1B1 and LS4-2C3 gener-
ated against the pSer129 αS epitope can cross react with NFL phosphorylated at Ser473. Antibodies EP1536Y, LS3-2C2 and LS4-2G12 generated against
the pSer129 αS epitope reacted only with phosphorylated WT αS. Antibody LS7 generated against the pSer129 αS epitope detected both phospho-
and non-phospho-αS. The mobility of molecular mass markers are shown on the left
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Fig. 3 Characterization of the specificity of novel pSer129 αS antibodies by immunoblotting analyses using biochemically fractionated brainstem/
spinal cord mouse tissues. Brainstem/spinal cord from an αS null (αS KO), a WT, a 2 month old non-symptomatic M83 (M83) and a 12 month
old motor impaired M83 (M83-I) mouse were biochemically fractionated into high salt (HS), high salt/Triton X-100 (HS/T) and SDS/urea (SDS/U)
fractions as described in “Materials and methods”. 10 μg of HS and HS/T, and 5 μg of SDS/U fractions were resolved onto 13 % polyacrylamide
gels and analyzed by immunoblotting with each antibody indicated above. The protein band identified by an arrowhead is αS, while an asterisk
depicts NFL. The mobility of molecular mass markers are shown on the left
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Fig. 4 Characterization of the specificity of novel pSer129 αS antibodies by immunoblotting analyses using biochemically fractionated cerebral
cortex mouse tissues. Cerebral cortex from an αS null (αS KO), a WT, a 2 month old non-symptomatic M83 (M83) and a 12 month old motor
impaired M83 (M83-I) mouse were biochemically fractionated into high salt (HS), high salt/Triton X-100 (HS/T) and SDS/urea (SDS/U) fractions
as described in “Materials and methods”. 10 μg of HS and HS/T and 5 μg of SDS/U fractions were resolved onto 13 % polyacrylamide gels and
analyzed by immunoblotting with each antibody indicated above. The protein band identified by an arrowhead is αS, while an asterisk depicts
NFL. The mobility of molecular mass markers are shown on the left
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Carlsbad, CA). Nuclei were counterstained with 4′,6-dia-
midino-2-phenylindole (DAPI; Invitrogen, Carlsbad, CA),
and coverslips were mounted using Fluoromount-G
(Southern Biotech, Birmingham, AL). Immunofluores-
cence images were captured with an Olympus BX51 fluor-
escence microscope mounted with a DP71 digital camera
(Olympus, Center Valley, PA).
Results
Assessment of NFL and αS phosphorylation by casein
kinase II and polo-like kinases
CKII was previously reported as a major kinase respon-
sible for the phosphorylation of αS, more specifically at
Ser129 [19, 36, 37], and NFL [38–40]. Characterization
of NFL phosphorylation by CKII was predominantly fo-
cused on Ser473, which is the major phosphorylation
site in NFL in vivo [40, 41]. Phosphorylation of αS at
Ser129 can be mediated by many additional kinases [19,
42–47] but some PLKs appear to be quite efficient in
driving this modification [42, 43, 47]. To compare the
relative abilities of CKII and PLK 1, 2 and 3 to phosphor-
ylate αS and NFL, and use this information to generate
phosphorylated protein that can be used to assess the spe-
cificity of novel antibodies (see below), we assessed the
relative but quantitative in vitro phosphorylation of αS
and NFL with CKII and PLK 1, 2 and 3 (Fig. 1b). In these
parallel kinase conditions, PLK3 was the most efficient at
phosphorylating αS at a stoichiometric ratio of close to 1
mol of phosphate per 1 mol of protein. This phosphoryl-
ation was almost completely abolished for S129A αS indi-
cating that Ser129 is the major αS phosphorylation site for
PLK3. NFL was phosphorylated by PLK1 and PLK3 at
multiple amino residues as shown by the greater stoichio-
metric molecular ratio of approximately 4.7 and 6, re-
spectively. In addition, the presence of the S473A
mutation in NFL only reduced the amount of phosphate
incorporation by PLK1 and PLK3 by 0.45 and 0.37 mol
phosphate/mol protein respectively, indicating that Ser473
is not the major site targeted by these kinases. CKII phos-
phorylated NFL at a ratio of 1.28 mol phosphate/mol pro-
tein, and this was reduced to 0.61 for S473A NFL
indicating that, while this is not the only site, it is the
major target site for this kinase.
Generation of novel pSer473 NFL and pSer129 αS
antibodies
To provide more reagents to study the contribution of
aberrant accumulation and/or distributions of αS and
NFL in neurodegenerative diseases, we generated novel
monoclonal antibodies against the pSer473 epitope in
Fig. 5 Characterization of the specificity of novel pSer129 αS antibodies by immunoblotting analyses using total lysates of cortex and brainstem/
spinal cord tissues from WT and NFL null mice. Cerebral cortex and brainstem/spinal cord (BS/SC) from a WT, an NFL null (NFL KO) and an αS null
(αS KO) mouse were dissected and lysed in 2 % SDS/ 50 mM Tris pH 7.5 as described in “Materials and methods”. Equal amounts of proteins (5
μg) from each sample was resolved onto 10 % polyacrylamide gels and analyzed by immunoblotting with each antibody indicated above. The
protein band identified by an asterisk depicts NFL. The mobility of molecular mass markers are shown on the left
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NFL and the pSer129 epitope in αS. For the pSer473
NFL epitope we used a synthetic peptide with phosphor-
ylated serine and the adjacent 7 amino acids residues on
either side in the human NFL sequence (Table 1). We
identified and characterized (see below) one clone
termed 4F8 that was relatively specific for pSer473 in
NFL.
For the pSer129 αS epitope we performed multiple
attempts to produce αS antibodies that were 1)
phospho-specific and 2) relatively specific in detecting
Lewy pathology. For our most successful approach, the
mice were first immunized with the pSer129long peptide
(αS residues 121–137) then 3 weeks later with the
pSer129short peptide (αS residues 124–134; Table 1).
The final IP injection used a 1:1 ratio of the 2 peptides
and the initial ELISA antibody screen used the pSer129-
long peptide. We immunized several mice using this strat-
egy and kept the most promising hybridomas from our
initial ELISA and IHC screens for further characterization.
We have denoted these antibodies LS, meaning long
then short to indicate the peptides that were used for
immunization.
Characterization of novel monoclonal antibody
specificities using phosphorylated recombinant proteins
To confirm our findings from the in vitro kinase reac-
tions and initially characterize the specificity of the 4F8
antibody, we conducted immunoblotting analysis with
NFL and S473A NFL individually phosphorylated with
CKII and PLK1, 2 and 3 (Fig. 1c). As expected, the signal
was the weakest with PLK2 and the signal was abolished
for S473A NFL phosphorylated with any of these kinases
indicating that 4F8 is specific for NFL phosphorylated at
Ser473. Immunoblotting with the previously generated
pSer129 αS antibody 81A [19] was consistent with the in
vitro radioactivity kinase studies in terms of relative
phosphorylation of αS by these kinases (Fig. 1d). These
results show that PLK3 strongly phosphorylates both
NFL at Ser473 and αS at Ser129, and that CKII is the
preferred kinase for NFL at this site. Therefore we chose
to use these kinase reactions to further screen the speci-
ficity of our novel antibodies.
We performed immunoblot analyses of CKII and
PLK3 kinase reactions with WT and S473A NFL, and
WT and S129A αS (Fig. 2). Immunoblots with anti-NFL
antibody NR4 and anti-αS antibody Syn 204 are included
to demonstrate the respective proteins. In the immuno-
blots loaded with CKII reactions, 4F8 appeared specific
for phosphorylated NFL, however the blots with the
PLK3 reactions showed that it can also detect αS phos-
phorylated at Ser129. As previously published, 81A also
cross reacted with NFL phosphorylated at Ser473 [18],
particularly when phosphorylated by CKII. LS3-2C2 and
the commercially available EP1536Y were specific for αS
phosphorylated at Ser129. LS7 reacted with αS inde-
pendent of its phosphorylation state. Antibodies LS11,
LS4-1B1 and LS4-2C3 were specific for αS phosphory-
lated at Ser129, however they could also react to some
extent with NFL phosphorylated at Ser473. LS4-2G12
only showed reactivity with αS phosphorylated at Ser129
by PLK3, but it did not react with αS modified with CKII
due to its low level of phosphorylation, suggesting that it
is a weaker antibody.
Assessment of antibody specificity using biochemically
fractionated mouse nervous tissue
To assess for the more global specificity of the new anti-
bodies, we performed immunoblot analyses of sequen-
tially fractionated mouse brainstem/spinal cord (Fig. 3)
and cerebral cortex (Fig. 4) tissue from αS null (αS KO),
WT, 2 month old non-symptomatic M83 (M83) and
12 month old motor-impaired M83 (M83-I) mice. The
M83-I mouse contains pathological αS aggregates pre-
dominantly in the brainstem/spinal cord [25]. Immuno-
blots with anti-NFL antibody NR4 and anti-human αS
antibody Syn 204 are included to demonstrate the pres-
ence and distribution of these respective proteins. In
these analyses, 4F8 was quite specific, detecting predom-
inantly NFL and only a very faint phospho-αS band in
the brainstem/spinal cord SDS/U fraction of the M83-
I mouse (Fig. 3). LS7 showed a similar pattern of reactivity
to Syn 204, again indicating that it is not phospho-specific
(Figs. 3 and 4). Antibodies LS4-1B1, LS4-2C3 and 81A
could all react with pathological αS that accumulates in
the brainstem/spinal cord SDS/U fraction of M83-I mice
(Fig. 3), but they also cross reacted to some extent with
phosphorylated NFL present in the brainstem/spinal cord
and cortex of all these mice (Figs. 3 and 4). This cross-
reactivity to NFL was confirmed by immunoblotting of
total brainstem/spinal cord and cortex tissues from WT,
(See figure on previous page.)
Fig. 6 Comparison of novel antibodies in detecting pathological inclusions in αS transgenic mice injected with αS fibrils in the periphery
(intramuscular) or the brain (hippocampus). Representative images of IHC staining of tissue from M83 αS transgenic mice injected in the
gastrocnemius muscle, and M83 and M20 αS transgenic mice injected in the hippocampus with recombinant preformed αS fibrils. Images were
taken from the brainstem (muscle injection) and the hippocampus (hippocampal injection). Antibodies EP1536Y and 81A showed robust staining
of induced inclusions (arrows). LS7 stained inclusions weakly with higher general labeling. Novel antibodies raised against the pSer129 αS epitope
LS4-2G12, LS3-2C2 and LS4-2C3 or to the p473 NFL epitope all stained the induced inclusions in these models. Scale bar = 50 μm
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NFL null and αS null mice (Fig. 5). LS11 detected aggre-
gated phosphorylated αS (Fig. 3) but also cross-reacted
with NFL, as shown by the reduction in signal of the
~70 kDa band in the total brainstem/spinal cord extract
from the NFL null mice (Fig. 5). However, it also reacted
with another protein of approximately the same size as
NFL prevalent in the cortex, even in NFL and αS null
mice (Fig. 5). This protein also has a different biochemical
fractionation profile compared to NFL in the cortex
(Fig. 4). Antibodies LS11, LS3-2C2, LS4-1B1, LS4-2C3
and LS4-2G12 also detected a ~30 kDa non-αS protein.
LS3-2C2 weakly labeled a few additional protein bands in
the brainstem/spinal cord lysates of all mice indicating
that these are not αS. Overall, LS4-2G12 appeared to be
the most specific new phospho-αS antibody.
IHC analyses of mouse and human nervous tissue with
new pSer473 NFL and pSer129 αS antibodies
Using our new and previously generated pSer129 αS
antibodies and the new pSer473 NFL antibody 4F8, we
performed IHC analyses on a cohort of mouse tissue de-
rived from αS transgenic and WT mice (Table 2) and
human autopsy cases with a diagnosis of PD, DLB or
MSA (Table 3). Our mouse tissue cohort, included pre-
viously described [26–28] tissue of αS transgenic mice
injected with αS fibrils either in the gastrocnemius
muscle (M83 line) or hippocampus that induces the for-
mation of αS inclusion pathology (M83 and M20 lines;
Fig. 6), and naïve αS transgenic and WT mice (Fig. 7).
The tissue in this cohort was fixed with 150 mM NaCl/
70 % ethanol. The staining revealed that all of the anti-
αS antibodies tested were able to reliably stain αS inclu-
sion pathology in this cohort. Likewise, 4F8 stained
many inclusions. EP1536Y also stained inclusions,
however in some sections it had a tendency to non-
specifically react with cellular nuclei (see Fig. 7).
Phosphorylation-independent antibody, LS7 stained in-
clusions, but weaker than the phospho-specific anti-
bodies. Interestingly, the general baseline staining of LS7
was only evident in the αS transgenic and not in the
WT mice (Fig. 7), because it is specific for human αS
(Additional file 1: Figure S1). Antibodies that could
cross-react with phospho-NFL such as LS4-2C3, as
well as LS3-2C2 which does not detect phospho-NFL,
also demonstrated staining of axonal processes similar
to 4F8 (Fig. 7).
For our human autopsy cohort, we performed IHC on
sections of midbrain (PD and DLB), cingulate cortex
(DLB; Fig. 8), and pons and cerebellum (MSA; Fig. 9).
All of the antibodies tested showed robust reactivity to
the αS inclusion pathology in the PD and DLB cases,
apart from LS3-2C2 which displayed weaker staining
particularly in the DLB cingulate cortex (Fig. 8). All
pSer129 αS antibodies stained GCIs in the MSA tissue;
however the strength of the signal differed extensively
between the antibodies (Fig. 9). For example, EP1536Y
showed the strongest staining, while LS4-2G12 and
LS3-2C2 showed weaker staining, especially in the
cerebellum. Although LS4-2C3 labeled αS inclusions
well in the pons, its reactivity with NFL made it diffi-
cult to make out many inclusions within the cerebel-
lum; the axonal staining being on par with that of
4F8. 4F8 itself was able to stain some GCIs, however
these were rare, and whether this is really pSer473
NFL staining, or just cross-reactivity with pSer129 αS
remains in question.
Using mouse tissue fixed using formalin or ethanol
(150 mM NaCl/70 % ethanol), we confirmed that all the
antibodies could be used to stain tissue preserved with
both types of fixatives (Additional file 2: Figure S2).
Immunofluorescence analyses of αS aggregation in
primary neuronal-glial cultures
Using only the new pSer129 αS antibodies that do not
cross-react with phospho-NFL, we determined if these
could be used to monitor the aggregation of αS in pri-
mary neuronal-glial cultures induced by the addition of
exogenous αS preformed fibrils. LS4-2G12 readily de-
tected neuronal phosphorylated αS aggregates, and
the paucity of these inclusions in cultures from αS
null mice confirmed that these were comprised of en-
dogenous αS (Fig. 10). Antibody LS3-2C2 could also
detect inclusions comprised of endogenous αS in pri-
mary neuronal-glial cultures treated with exogenous
αS fibrils, but this antibody was less useful due to the
non-specific cross-reactivity with cellular nuclei (Additional
file 3: Figure S3).
(See figure on previous page.)
Fig. 7 Comparison of pSer129 antibody IHC staining using naïve αS transgenic and WT mice. Representative images of IHC staining of brainstem
tissue from a 7 month old non-symptomatic homozygous M83 mouse (M83 unimpaired), a 12 month old motor impaired homozygous M83
mouse (M83 motor impaired) and a WT mouse. All antibodies stained perikaryal and neuritic inclusions in the M83 diseased mouse. LS7 showed
weaker reactivity to αS pathology than the other antibodies and showed stronger diffused signal in the αS transgenic mice compared to the WT
mouse. LS3-2C2 also showed weak staining of pathology. In addition to the pathology in motor impaired M83 mouse, antibodies 4F8, LS3-2C2,
LS4-2C3 and 81A also labeled neuronal projections even in WT mice (arrowheads). EP1536Y exhibited some nuclear staining in some mouse
sections (arrows), as did LS3-2C2, but much weaker than EP1536Y (eg. see arrows in the M83 unimpaired mouse). Scale bar = 50 μm
Rutherford et al. Acta Neuropathologica Communications  (2016) 4:80 Page 13 of 20
Fig. 8 (See legend on next page.)
Rutherford et al. Acta Neuropathologica Communications  (2016) 4:80 Page 14 of 20
Discussion
In this study we addressed the need for specific, well
characterized antibodies to pathological αS by generating
monoclonal antibodies against the pSer129 αS epitope,
as most existing pSer129 αS antibodies have been re-
ported to cross react with additional proteins [4, 18]. For
example, we previously showed that pSer129 antibody,
81A cross-reacts with pSer473 NFL [18] while antibody
MJF-R13(8–8) that does not detect phosphorylated NFL,
is still highly non-specific and cannot be used to assess
αS pathology [4]. The difficulty of making antibodies
specific to pSer129 αS is not entirely surprising. This site
can be phosphorylated in vitro by multiple serine/threo-
nine kinases, including CKI and II, PLK 1, 2 and 3, and
G-protein coupled receptor kinases (GRKs) [19, 37, 42–
45, 47]. Each of these kinases in turn can phosphorylate
numerous protein targets, which contain a certain level
of homology in the amino acid sequence surrounding
each phosphorylation site. As such, we show that both
αS and NFL can be phosphorylated by CKII, PLK2 and
PLK3, but Ser129 in αS is a preferential site for PLK2
and PLK3, demonstrating higher phosphorylation effi-
ciency. Comparatively, CKII preferentially phosphory-
lates Ser473 in NFL and this site can be phosphorylated
by PLK1, 2 and 3, but these enzymes prefer to modify
other sites within NFL.
The pSer473 NFL epitope contains some sequence
identity to pSer129 αS (Fig. 1a), but the fact that a dis-
proportionate number of antibodies to pSer129 αS react
with pSer473 NFL indicates that these two epitopes
share additional and specific conformational cues be-
yond simply the primary sequence. This notion is further
demonstrated by the findings that antibody 4F8 gener-
ated against the pSer473 NFL epitope can cross-react, to
some extent, with pSer129 in αS. In addition, most of
the pSer129 αS antibodies that react with pSer473 NFL
are relatively specific for only these 2 epitopes, even on
immunoblot analysis of whole brain and spinal cord
lysates, and they do not react with other phospho-
epitopes within NFL that can be phosphorylated by
PLKs. The complications in using pSer129 αS antibodies
that are confounded by pSer473 NFL reactivity in
staining tissues are compounded by 1) the high abun-
dance of NFL in the nervous tissue, 2) that Ser473 in
NFL is intrinsically highly phosphorylated [41], and 3)
neurofilaments are natively assembled into fibrillar
structures that can resemble αS polymerized to form
pathological inclusions.
Our studies have yielded and characterized 2 new
monoclonal antibodies, LS3-2C2 and LS4-2G12, in
addition to the commercial antibody EP1536Y that does
not cross-react with phosphorylated NFL. However, LS3-
2C2 reacted with additional non-αS proteins and its ten-
dency to non-specifically react with cellular nuclei renders
it less useful for some studies. The issue of non-specific
staining of cellular nuclei was intermittently observed with
EP1536Y. In addition, pSer129 antibodies LS11, LS3-2C2,
LS4-1B1, LS4-2C3 and LS4-2G12 also detect a ~30 kDa
non-αS protein in mouse nervous tissue, which was most
obvious in the αS null mouse. Nevertheless, pSer129 αS
antibody LS4-2G12 was the most specific of the antibodies
tested, but it did not stain pathological inclusions as
strongly as other pSer129 αS antibodies, which could
be due to lower affinity and/or cross-reactivity. These
new pSer129 αS antibodies will be very useful tools,
especially in the research community where they are
commonly used for tracking the induction and spread
of αS pathology in experimental models. The cross-
reactivity of pSer129 αS antibodies is less of a concern in a
clinical setting, where diagnosis of synucleinopathy is de-
termined using a well-established set of non-phospho αS
antibodies.
To our knowledge, antibody 4F8 is the first monoclo-
nal pSer473 NFL antibody reported, although a poly-
clonal antibody to this epitope was reported in 1999
[40]. This antibody will be a very useful tool when used
together with pSer129 αS antibodies that do not cross-
react with phosphorylated NFL, to expand studies of
aberrant phosphorylated neurofilaments within neuro-
pathological inclusions. NFL is the core neurofilament
subunit required for proper neurofilament assembly
and neurofilaments are present in many different
types of inclusions associated with neurodegenerative
diseases [48], for example neurofilament inclusion
disease (NFID), a rare, sporadic disease with features
of frontotemporal dementia [49–53]. In addition,
neuroaxonal spheroids comprised of bundles of neu-
rofilaments are a common feature in patients with
amyotrophic lateral sclerosis [54, 55] and neuroaxonal
dystrophies [56–58]. Furthermore, neurofilaments typ-
ically accumulate within neurofibrillary tangles of Alz-
heimer’s disease [59, 60].
Conclusions
In conclusion, even though pSer129 αS antibody staining
can be a very sensitive tool for detecting aberrantly
(See figure on previous page.)
Fig. 8 IHC analyses of brain sections of individuals with Parkinson’s disease and dementia with Lewy bodies. Representative IHC staining of brain
tissue sections from PD and DLB patients. Images were taken from the midbrain (PD and DLB) or cingulate cortex (DLB only). All of the
antibodies stained LBs within dopaminergic neurons in the midbrain sections for both PD and DLB. Arrows show LBs in some examples within
cells containing neuromelanin. Scale bar = 50 μm
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aggregated αS and pathological inclusions, specificity is a
critical issue that needs to be considered for accurate
assessments. The intrinsic similarities in primary se-
quence surrounding this site to other proteins that are
phosphorylated by mutual kinases and the apparent
additional structural homology to the pSer473 NFL epi-
tope complicates the generation of highly specific anti-
bodies. Nevertheless, from a series of new monoclonal
antibodies, we were able to identify LS4-2G12 that is
relatively specific and useful in detecting αS aggregates
in human brains and experimental models. However,
given the varied specificity and properties of pSer129 αS
antibodies, as demonstrated here, it should be preferred
as a common practice to use a combination of several
pSer129 αS antibodies in addition to an αS antibody to
accurately assess neuropathological changes in αS.
(See figure on previous page.)
Fig. 9 IHC analyses of brain sections of individuals with multiple system atrophy. Representative IHC staining of brain tissue sections from MSA
patients. Images were taken from the pons or cerebellum. Arrows show GCIs. All of the antibodies stained inclusions, to some extent. EP1536Y
showed the strongest staining. 4F8 stained only rare inclusions, but abundantly labeled axons (arrowheads). Antibodies 81A and LS4-2C3 also
displayed strong reactivity to axons in the cerebellum. Antibodies LS4-2G12 and LS3-2C2 displayed weaker staining of inclusions in the cerebellum.
Scale bar = 50 μm
Fig. 10 Analysis of the induction of endogenous αS aggregation by treatment with exogenous αS mouse fibrils in primary neuronal-glial cultures
using antibody LS4-2G12. Primary neuronal-glial cultures from WT mice or αS null mice were cultured for 6 days and either maintained without
other treatment for 8 days (Ct) or treated with mouse αS fibrils (20 μg/ml; αS Fib) for 8 days. Double immunofluorescence analysis with antibodies
LS4-2G12 (red) and specific neuronal marker βIII-tubulin (green) was performed. Cells were also counterstained with DAPI and merged images
are shown. Higher magnification LS4-2G12 and merged images are shown on the far right. Arrows depict induced labeled αS aggregates. Scale
bar = 100 μm and 250 μm for the higher magnification images on the right
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Additional files
Additional file 1: Figure S1. Specificity of novel antibody LS7 for
human αS. (a) Recombinant human and mouse αS (50 ng) were resolved
onto 13 % polyacrylamide gels and analyzed by immunoblotting with LS7
and anti-αS antibody SNL-4 (residues 2–12 of αS). The mobility of molecular
mass markers are shown on the left. (b) Sequence of the pSer129long peptide
(human αS) with the corresponding mouse αS sequence underneath. The line
indicates amino acids that are not shared. (TIF 216 kb)
Additional file 2: Figure S2. IHC analyses showing antibody reactivity
in formalin and ethanol fixed tissues. Representative IHC staining of the
brainstem of M83 mice injected in the gastrocnemius muscle with αS
fibrils. The tissue of one mouse (left) was fixed in 150 mM NaCl/70 %
ethanol and the other (right) was fixed in formalin. All of the antibodies
were able to stain pathology in both formalin and ethanol fixed tissue,
however some staining appeared weaker in the formalin fixed tissue
(LS4-2G12 and LS3-2C2). Scale bar = 50 μm. (TIF 9583 kb)
Additional file 3: Figure S3. Analysis of the induction of endogenous
αS aggregates with exogenous αS mouse fibrils in primary neuronal-glial
cultures using antibody LS3-2C2. Primary neuronal-glial cultures from WT
mice or αS null mice were cultured for 6 days and either maintained
without other treatment for 8 days (Ct) or treated with mouse αS fibrils
(20 μg/ml; αS fib) for 8 days. Double immunofluorescence analysis with
antibodies LS3-2C2 (red) and specific neuronal marker βIII-tubulin (green)
was performed. Cells were also counterstained with DAPI and merged
images are shown. Higher magnification merged images are shown
on the far right. Arrows depict induced labeled αS aggregates and
arrowheads depict nuclear staining. Bar = 100 μm and 250 μm for the
higher magnification images on the right. (TIF 7508 kb)
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